Share on StockTwits

Marinus Pharmaceuticals’ (NASDAQ:MRNS) quiet period will expire on Tuesday, September 9th. Marinus Pharmaceuticals had issued 5,625,000 shares in its public offering on July 31st, Stock Ratings News reports. The total size of the offering was $45,000,000 based on an initial share price of $8.00. During the company’s quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

A number of research firms have recently commented on MRNS. Analysts at JMP Securities initiated coverage on shares of Marinus Pharmaceuticals in a research note on Tuesday, August 26th. They set an “outperform” rating and a $14.00 price target on the stock. Separately, analysts at Stifel Nicolaus initiated coverage on shares of Marinus Pharmaceuticals in a research note on Monday, August 25th. They set a “buy” rating and a $11.00 price target on the stock. Finally, analysts at Janney Montgomery Scott initiated coverage on shares of Marinus Pharmaceuticals in a research note on Monday, August 25th. They set a “buy” rating and a $13.00 price target on the stock.

Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) remained flat at $7.38 during during mid-day trading trading on Thursday. 291 shares of the company’s stock traded hands. Marinus Pharmaceuticals has a 52 week low of $7.05 and a 52 week high of $8.16. The stock’s 50-day moving average is $7.98 and its 200-day moving average is $7.98. The company’s market cap is $101.7 million.

Marinus Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. The Company is focused on developing and commercializing neuropsychiatric therapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.